Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2020-03-10 Share Issue/Capital Cha…
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Episurf Medical offentliggör prospekt
Share Issue/Capital Change Classification · 1% confidence The document is a press release titled "Episurf Medical offentliggör prospekt" (Episurf Medical publishes prospectus) concerning a rights issue ("Företrädesemissionen"). It explicitly states that the prospectus has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen) and details the terms of the share issue, including the preliminary timeline and where to find the full prospectus. Since the document is an announcement about the publication of a formal offering document (the prospectus) related to a capital change (share issue), it strongly aligns with the definition of Capital/Financing Update (CAP). Although it mentions the prospectus, the primary focus is the financing activity itself (rights issue and directed issue). It is not the full prospectus, nor is it a general regulatory filing (RNS) or a simple dividend notice (DIV). Therefore, CAP is the most appropriate classification.
2020-03-10 Swedish
Summary from extraordinary general meeting of Episurf Medical AB (publ)
Share Issue/Capital Change Classification · 1% confidence The document is a summary of an Extraordinary General Meeting (EGM) held by Episurf Medical AB. It details the resolutions passed, specifically regarding a new share issue with preferential rights (Rights Issue) and a directed share issue. While it mentions the meeting results, the primary focus is on the capital structure changes and the issuance of new shares. Therefore, it is best classified as a Share Issue/Capital Change announcement.
2020-03-10 English
Kommuniké från extra bolagsstämma i Episurf Medical AB (publ)
Share Issue/Capital Change Classification · 1% confidence The document is a press release from Episurf Medical announcing the results of an extraordinary general meeting (extra bolagsstämma). It details the approval of a rights issue (Företrädesemissionen) and a directed share issue (Riktad Nyemission), as well as amendments to the articles of association. While it discusses capital changes, it is primarily a report on the outcomes of a shareholder meeting, which falls under the category of AGM/EGM information and voting results.
2020-03-10 Swedish
Positive results from follow-up of 30 patients in a Swedish multi-centre clinical trial of the Episealer® Knee implant
Regulatory Filings Classification · 1% confidence The document is a press release from Episurf Medical announcing positive results from a clinical trial regarding their Episealer® Knee implant. It details patient outcomes, follow-up periods, and mentions that the principal investigator will compile results for submission to a scientific journal. The final paragraph states: "This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication... on 8 March 2020." This structure—a brief announcement of new, material, non-financial information that is required to be made public under market regulations (like MAR)—is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (10-K, IR, ER, etc.). Since it is a formal announcement of material information required by regulation, and it is not a specific report type like an Earnings Release (ER) or Interim Report (IR), the most appropriate general category is Regulatory Filings (RNS). The document length (4094 chars) is short, but it is conveying the primary information directly, not just announcing a separate, attached report.
2020-03-08 English
Positiva resultat från uppföljning av 30 patienter i en svensk multicenterstudie av knäimplantatet Episealer®
Regulatory Filings Classification · 1% confidence The document is a press release from Episurf Medical announcing positive results from a clinical follow-up study on their Episealer® knee implant involving 30 patients. It details the study's findings, patient outcomes (EQ5D, VAS, KOOS scores), and includes quotes from the CEO. The final paragraph states: "Denna information är sådan information som Episurf Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such information that Episurf Medical AB is obliged to disclose pursuant to the EU's Market Abuse Regulation), indicating a regulatory disclosure. Since it is an announcement of clinical results and not a full financial report (10-K, IR) or a transcript (CT), it fits best as a general regulatory announcement or press release. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a mandatory disclosure that isn't a specific financial or corporate governance filing type listed, although it shares characteristics with an Earnings Release (ER) in terms of reporting period results, it focuses on clinical data rather than financial performance highlights. However, since it is a specific announcement mandated by market abuse regulation, RNS (Regulatory Filings) is the best fit as a general regulatory disclosure.
2020-03-08 Swedish
Viktigt patentbeviljande i Europa för Episurf Medical inom 3D-visualisering
Regulatory Filings Classification · 1% confidence The document is a short announcement in Swedish regarding the intention of the European Patent Office (EPO) to grant a new patent to Episurf Medical concerning 3D visualization technology for joint implants. It includes quotes from management and standard company boilerplate information. Crucially, the final paragraph states: "Denna information är sådan information som Episurf Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation). This indicates it is a mandatory regulatory disclosure. Since the content is a specific announcement about a patent grant, and it doesn't fit the definitions for ER, IR, 10-K, or specific corporate actions like DIV or DIRS, the most appropriate general category for a mandatory regulatory disclosure that doesn't fit elsewhere is 'Regulatory Filings' (RNS). The document length is short (2035 chars), but it is the primary announcement itself, not an announcement *about* another report, so the RPA rule does not strictly apply here over RNS for a specific regulatory event disclosure.
2020-03-06 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.